Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-targeting CAR T cells (Fuda Cancer Hospital)
- Development stage
- Unknown
- Lead developer
- Fuda Cancer Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19-targeting CAR T cells (Fuda Cancer Hospital) is an autologous, second-generation chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of B-cell malignancies. The therapy involves the ex vivo genetic modification of a patient's own T lymphocytes to express a CAR specific for the CD19 antigen, a surface protein consistently expressed on B-cell lymphomas. Upon re-infusion, these engineered cells recognize and bind to CD19-positive cells, triggering T-cell activation, proliferation, and the targeted destruction of the malignant B cells. It is currently being investigated in clinical trials for patients with relapsed or refractory B-cell lymphoma.
- Other names
- CD19-targeting 2nd generation CAR T cellsCD-19-targeting 2nd generation CAR T cellsCD 19-targeting 2nd generation CAR T cellsCD19 CAR-T cellsCD-19 CAR-T cellsCD 19 CAR-T cells
02
Targets
Beyond the preview
Go deeper on CD19-targeting CAR T cells (Fuda Cancer Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-targeting CAR T cells (Fuda Cancer Hospital).